Basic Information
| Drug ID | DDPD00820 |
|
| Drug Name | Tadalafil | |
| Molecular Weight | 389.404 | |
| Molecular Formula | C22H19N3O4 | |
| CAS Number | 171596-29-5 | |
| SMILES | [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1 | |
| External Links | ||
| DRUGBANK | DB00820 | |
| PubChem Compound | 110635 | |
| PDR | 2115 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 1.7 | - | 1.7 | - | DRUGBANK |
| Melting Point | 301.5 | ℃ | 301-302 | ℃ | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| C Max | 378.0 | ng/ml | 378.0 | ng/ml | Oral single dose; | The Pharmacological Basis of Therapeutics | |
| T Max | 2.0 | h | 2(0.5-6) | h | Oral single dose; | DRUGBANK | T Max | 2.0 | h | 2.0 | h | Oral single dose; | The Pharmacological Basis of Therapeutics |
| Clearance | 2.5 | L/h | 2.5 | L/h | PO, oral; | DRUGBANK | Clearance | 0.0354 | L/h/kg | 0.59 | ml/min/kg | apparent clearance; hydrolysis; | RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics |
| Volume of Distribution | 63.0 | L | 63.0 | L | DRUGBANK | Volume of Distribution | 0.89 | L/kg | 0.89 | L/kg | Apparent volume of distribution; hydrolysis; | The Pharmacological Basis of Therapeutics |
| Half-life | 17.5 | h | 17.5 | h | DRUGBANK | Half-life | 17.5 | h | 17.5 | h | The Pharmacological Basis of Therapeutics |
| Toxicity LD50 | 2000.0 | mg/kg | 2000.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | |
| Eliminate Route | 61.0 | % | ~61 | % | Faeces excretion; | DRUGBANK | Eliminate Route | 36.0 | % | ~36 | % | Urinary excretion; | DRUGBANK |
| Protein Binding | 94.0 | % | 94 | % | DRUGBANK | Protein Binding | 94.0 | % | 94 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for adults | 40.0 | mg/day | 40 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for adults | 5.0 | mg/day | 5 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for adults | 20.0 | mg/day | 20 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for adults | 5.0 | mg/day | 5 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for geriatric | 40.0 | mg/day | 40 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for geriatric | 5.0 | mg/day | 5 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for geriatric | 20.0 | mg/day | 20 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
| Max dose for geriatric | 5.0 | mg/day | 5 | mg/day | PO, oral | Adcirca | tadalafil | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1